Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week
The FDA approved Veppanu, a Pfizer-Arvinas pill, for adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. The decision comes two days before Pfizer’s first-quarter earnings update. Veppanu is the first FDA-approved PROTAC therapy. Pfizer and Arvinas plan to select a third-party partner for commercialization.